Sterotherapeutics begins Phase II trial for ST-002 targeting Cushing’s Syndrome

US-based clinical-stage company Sterotherapeutics has announced the commencement of a Phase II clinical trial for its drug candidate, ST-002, for treating Cushing’s Syndrome, a rare endocrine disorder.